NATIONAL BANK OF CANADA /FI/
BankPosition in GALT — Galectin Therapeutics Inc
CIK 926171
MONTREAL, A8
Position in GALT
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$779,056
New position
Shares Held
167,900
first reported quarter
Ownership
0.166%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#20
of 98 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 100%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026NATIONAL BANK OF CANADA /FI/ holds $632,429,861 across 151 Biotechnology names. GALT ranks #16 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
1,096,025 | $205,263,562 | |
| 2 | MRNA |
Moderna, Inc.
|
1,424,802 | $99,778,883 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
2,773,874 | $98,167,400 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
172,898 | $85,883,622 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
125,812 | $78,448,813 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
52,467 | $15,794,140 | |
| 7 | GPCR |
Structure Therapeutics Inc.
|
215,800 | $11,581,986 | |
| 8 | ABCL |
AbCellera Biologics Inc.
|
1,233,014 | $9,679,159 |
All Filings in GALT
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $779,056 | 167,900 | Shares | Defined | 2026-08-10 | |
| No filing history on record for this holder in this stock. | ||||||